nodes	percent_of_prediction	percent_of_DWPC	metapath
Nadolol—ABCB1—melanoma	0.752	1	CbGaD
Nadolol—Colitis ischaemic—Docetaxel—melanoma	0.00438	0.034	CcSEcCtD
Nadolol—Dry skin—Vemurafenib—melanoma	0.00252	0.0196	CcSEcCtD
Nadolol—Hepatic enzyme increased—Temozolomide—melanoma	0.00204	0.0159	CcSEcCtD
Nadolol—Disorientation—Bleomycin—melanoma	0.00186	0.0145	CcSEcCtD
Nadolol—Dry eye—Temozolomide—melanoma	0.00179	0.0139	CcSEcCtD
Nadolol—Throat sore—Docetaxel—melanoma	0.00178	0.0139	CcSEcCtD
Nadolol—Oropharyngeal discomfort—Docetaxel—melanoma	0.00177	0.0138	CcSEcCtD
Nadolol—Alopecia—Vemurafenib—melanoma	0.00168	0.0131	CcSEcCtD
Nadolol—Lethargy—Dactinomycin—melanoma	0.00158	0.0123	CcSEcCtD
Nadolol—Amnesia—Carmustine—melanoma	0.00155	0.012	CcSEcCtD
Nadolol—Nasal congestion—Temozolomide—melanoma	0.00154	0.012	CcSEcCtD
Nadolol—Amnesia—Temozolomide—melanoma	0.00149	0.0116	CcSEcCtD
Nadolol—Diplopia—Carmustine—melanoma	0.00145	0.0113	CcSEcCtD
Nadolol—Cough—Vemurafenib—melanoma	0.00144	0.0112	CcSEcCtD
Nadolol—Bronchospasm—Bleomycin—melanoma	0.00142	0.011	CcSEcCtD
Nadolol—Oropharyngeal pain—Docetaxel—melanoma	0.00141	0.011	CcSEcCtD
Nadolol—Diplopia—Temozolomide—melanoma	0.0014	0.0109	CcSEcCtD
Nadolol—Affect lability—Temozolomide—melanoma	0.00138	0.0108	CcSEcCtD
Nadolol—Mood swings—Temozolomide—melanoma	0.00133	0.0103	CcSEcCtD
Nadolol—Dry skin—Temozolomide—melanoma	0.00129	0.01	CcSEcCtD
Nadolol—Hypotension—Vemurafenib—melanoma	0.00126	0.00982	CcSEcCtD
Nadolol—Abdominal distension—Temozolomide—melanoma	0.00122	0.0095	CcSEcCtD
Nadolol—Fluid retention—Docetaxel—melanoma	0.00122	0.0095	CcSEcCtD
Nadolol—Decreased appetite—Vemurafenib—melanoma	0.00117	0.00913	CcSEcCtD
Nadolol—Fatigue—Vemurafenib—melanoma	0.00116	0.00906	CcSEcCtD
Nadolol—Constipation—Vemurafenib—melanoma	0.00115	0.00898	CcSEcCtD
Nadolol—Pulmonary oedema—Docetaxel—melanoma	0.00114	0.00891	CcSEcCtD
Nadolol—Erectile dysfunction—Temozolomide—melanoma	0.00112	0.00869	CcSEcCtD
Nadolol—Depression—Carmustine—melanoma	0.00112	0.00868	CcSEcCtD
Nadolol—Agranulocytosis—Dactinomycin—melanoma	0.00112	0.00868	CcSEcCtD
Nadolol—Weight increased—Temozolomide—melanoma	0.0011	0.00859	CcSEcCtD
Nadolol—Depression—Temozolomide—melanoma	0.00108	0.00839	CcSEcCtD
Nadolol—Body temperature increased—Vemurafenib—melanoma	0.00107	0.0083	CcSEcCtD
Nadolol—Cardiac failure congestive—Docetaxel—melanoma	0.00103	0.00801	CcSEcCtD
Nadolol—Alopecia—Bleomycin—melanoma	0.00102	0.00792	CcSEcCtD
Nadolol—Hallucination—Carmustine—melanoma	0.001	0.00778	CcSEcCtD
Nadolol—Visual disturbance—Docetaxel—melanoma	0.000985	0.00766	CcSEcCtD
Nadolol—Asthenia—Vemurafenib—melanoma	0.000969	0.00754	CcSEcCtD
Nadolol—Visual impairment—Carmustine—melanoma	0.000969	0.00753	CcSEcCtD
Nadolol—Hallucination—Temozolomide—melanoma	0.000966	0.00752	CcSEcCtD
Nadolol—Cardiac failure—Docetaxel—melanoma	0.000957	0.00744	CcSEcCtD
Nadolol—Pruritus—Vemurafenib—melanoma	0.000955	0.00743	CcSEcCtD
Nadolol—Lethargy—Docetaxel—melanoma	0.000953	0.00741	CcSEcCtD
Nadolol—Alopecia—Dactinomycin—melanoma	0.000949	0.00738	CcSEcCtD
Nadolol—Visual impairment—Temozolomide—melanoma	0.000936	0.00728	CcSEcCtD
Nadolol—Diarrhoea—Vemurafenib—melanoma	0.000924	0.00719	CcSEcCtD
Nadolol—Tinnitus—Temozolomide—melanoma	0.000906	0.00704	CcSEcCtD
Nadolol—Dizziness—Vemurafenib—melanoma	0.000893	0.00695	CcSEcCtD
Nadolol—Alopecia—Carmustine—melanoma	0.000888	0.00691	CcSEcCtD
Nadolol—Cough—Bleomycin—melanoma	0.000875	0.0068	CcSEcCtD
Nadolol—Vomiting—Vemurafenib—melanoma	0.000859	0.00668	CcSEcCtD
Nadolol—Alopecia—Temozolomide—melanoma	0.000858	0.00668	CcSEcCtD
Nadolol—Dry skin—Docetaxel—melanoma	0.000856	0.00666	CcSEcCtD
Nadolol—Chest pain—Bleomycin—melanoma	0.000853	0.00664	CcSEcCtD
Nadolol—Rash—Vemurafenib—melanoma	0.000851	0.00662	CcSEcCtD
Nadolol—Dermatitis—Vemurafenib—melanoma	0.000851	0.00662	CcSEcCtD
Nadolol—Vision blurred—Carmustine—melanoma	0.000825	0.00641	CcSEcCtD
Nadolol—Oedema—Bleomycin—melanoma	0.000818	0.00636	CcSEcCtD
Nadolol—Nausea—Vemurafenib—melanoma	0.000802	0.00624	CcSEcCtD
Nadolol—Vision blurred—Temozolomide—melanoma	0.000797	0.0062	CcSEcCtD
Nadolol—Bronchospasm—Docetaxel—melanoma	0.000794	0.00617	CcSEcCtD
Nadolol—Anorexia—Bleomycin—melanoma	0.00078	0.00607	CcSEcCtD
Nadolol—Hypotension—Bleomycin—melanoma	0.000764	0.00595	CcSEcCtD
Nadolol—Oedema—Dactinomycin—melanoma	0.000763	0.00594	CcSEcCtD
Nadolol—Hypertension—Carmustine—melanoma	0.000755	0.00588	CcSEcCtD
Nadolol—Chest pain—Carmustine—melanoma	0.000745	0.00579	CcSEcCtD
Nadolol—Cough—Temozolomide—melanoma	0.000738	0.00574	CcSEcCtD
Nadolol—Paraesthesia—Bleomycin—melanoma	0.000735	0.00571	CcSEcCtD
Nadolol—Weight increased—Docetaxel—melanoma	0.000734	0.00571	CcSEcCtD
Nadolol—Hypertension—Temozolomide—melanoma	0.00073	0.00568	CcSEcCtD
Nadolol—Dyspnoea—Bleomycin—melanoma	0.000729	0.00567	CcSEcCtD
Nadolol—Anorexia—Dactinomycin—melanoma	0.000727	0.00566	CcSEcCtD
Nadolol—Oedema—Carmustine—melanoma	0.000714	0.00555	CcSEcCtD
Nadolol—Decreased appetite—Bleomycin—melanoma	0.000711	0.00553	CcSEcCtD
Nadolol—Dry mouth—Temozolomide—melanoma	0.000704	0.00548	CcSEcCtD
Nadolol—Pain—Bleomycin—melanoma	0.0007	0.00544	CcSEcCtD
Nadolol—Conjunctivitis—Docetaxel—melanoma	0.000699	0.00544	CcSEcCtD
Nadolol—Oedema—Temozolomide—melanoma	0.00069	0.00537	CcSEcCtD
Nadolol—Anorexia—Carmustine—melanoma	0.000681	0.0053	CcSEcCtD
Nadolol—Agranulocytosis—Docetaxel—melanoma	0.000671	0.00522	CcSEcCtD
Nadolol—Hypotension—Carmustine—melanoma	0.000667	0.00519	CcSEcCtD
Nadolol—Hyperhidrosis—Temozolomide—melanoma	0.000667	0.00519	CcSEcCtD
Nadolol—Decreased appetite—Dactinomycin—melanoma	0.000663	0.00516	CcSEcCtD
Nadolol—Fatigue—Dactinomycin—melanoma	0.000658	0.00512	CcSEcCtD
Nadolol—Anorexia—Temozolomide—melanoma	0.000658	0.00512	CcSEcCtD
Nadolol—Pain—Dactinomycin—melanoma	0.000652	0.00508	CcSEcCtD
Nadolol—Body temperature increased—Bleomycin—melanoma	0.000647	0.00503	CcSEcCtD
Nadolol—Insomnia—Carmustine—melanoma	0.000646	0.00502	CcSEcCtD
Nadolol—Paraesthesia—Carmustine—melanoma	0.000641	0.00499	CcSEcCtD
Nadolol—Dyspnoea—Carmustine—melanoma	0.000637	0.00495	CcSEcCtD
Nadolol—Insomnia—Temozolomide—melanoma	0.000624	0.00486	CcSEcCtD
Nadolol—Visual impairment—Docetaxel—melanoma	0.000622	0.00484	CcSEcCtD
Nadolol—Decreased appetite—Carmustine—melanoma	0.000621	0.00483	CcSEcCtD
Nadolol—Paraesthesia—Temozolomide—melanoma	0.00062	0.00482	CcSEcCtD
Nadolol—Dyspnoea—Temozolomide—melanoma	0.000615	0.00479	CcSEcCtD
Nadolol—Pain—Carmustine—melanoma	0.000611	0.00475	CcSEcCtD
Nadolol—Constipation—Carmustine—melanoma	0.000611	0.00475	CcSEcCtD
Nadolol—Dyspepsia—Temozolomide—melanoma	0.000607	0.00473	CcSEcCtD
Nadolol—Body temperature increased—Dactinomycin—melanoma	0.000603	0.00469	CcSEcCtD
Nadolol—Decreased appetite—Temozolomide—melanoma	0.0006	0.00467	CcSEcCtD
Nadolol—Fatigue—Temozolomide—melanoma	0.000595	0.00463	CcSEcCtD
Nadolol—Constipation—Temozolomide—melanoma	0.00059	0.00459	CcSEcCtD
Nadolol—Pain—Temozolomide—melanoma	0.00059	0.00459	CcSEcCtD
Nadolol—Asthenia—Bleomycin—melanoma	0.000587	0.00457	CcSEcCtD
Nadolol—Pruritus—Bleomycin—melanoma	0.000579	0.0045	CcSEcCtD
Nadolol—Alopecia—Docetaxel—melanoma	0.000571	0.00444	CcSEcCtD
Nadolol—Body temperature increased—Carmustine—melanoma	0.000565	0.00439	CcSEcCtD
Nadolol—Asthenia—Dactinomycin—melanoma	0.000547	0.00426	CcSEcCtD
Nadolol—Body temperature increased—Temozolomide—melanoma	0.000546	0.00424	CcSEcCtD
Nadolol—Diarrhoea—Dactinomycin—melanoma	0.000522	0.00406	CcSEcCtD
Nadolol—Vomiting—Bleomycin—melanoma	0.00052	0.00405	CcSEcCtD
Nadolol—Rash—Bleomycin—melanoma	0.000516	0.00401	CcSEcCtD
Nadolol—Dermatitis—Bleomycin—melanoma	0.000515	0.00401	CcSEcCtD
Nadolol—Asthenia—Carmustine—melanoma	0.000512	0.00399	CcSEcCtD
Nadolol—Syncope—Docetaxel—melanoma	0.000504	0.00392	CcSEcCtD
Nadolol—Asthenia—Temozolomide—melanoma	0.000495	0.00385	CcSEcCtD
Nadolol—Loss of consciousness—Docetaxel—melanoma	0.000494	0.00384	CcSEcCtD
Nadolol—Cough—Docetaxel—melanoma	0.000491	0.00382	CcSEcCtD
Nadolol—Diarrhoea—Carmustine—melanoma	0.000489	0.0038	CcSEcCtD
Nadolol—Pruritus—Temozolomide—melanoma	0.000488	0.0038	CcSEcCtD
Nadolol—Nausea—Bleomycin—melanoma	0.000486	0.00378	CcSEcCtD
Nadolol—Hypertension—Docetaxel—melanoma	0.000485	0.00378	CcSEcCtD
Nadolol—Vomiting—Dactinomycin—melanoma	0.000485	0.00377	CcSEcCtD
Nadolol—Rash—Dactinomycin—melanoma	0.000481	0.00374	CcSEcCtD
Nadolol—Chest pain—Docetaxel—melanoma	0.000479	0.00372	CcSEcCtD
Nadolol—Dizziness—Carmustine—melanoma	0.000472	0.00367	CcSEcCtD
Nadolol—Diarrhoea—Temozolomide—melanoma	0.000472	0.00367	CcSEcCtD
Nadolol—Dry mouth—Docetaxel—melanoma	0.000468	0.00364	CcSEcCtD
Nadolol—Oedema—Docetaxel—melanoma	0.000459	0.00357	CcSEcCtD
Nadolol—Dizziness—Temozolomide—melanoma	0.000456	0.00355	CcSEcCtD
Nadolol—Vomiting—Carmustine—melanoma	0.000454	0.00353	CcSEcCtD
Nadolol—Nausea—Dactinomycin—melanoma	0.000453	0.00353	CcSEcCtD
Nadolol—Shock—Docetaxel—melanoma	0.000452	0.00351	CcSEcCtD
Nadolol—Rash—Carmustine—melanoma	0.00045	0.0035	CcSEcCtD
Nadolol—Dermatitis—Carmustine—melanoma	0.00045	0.0035	CcSEcCtD
Nadolol—Vomiting—Temozolomide—melanoma	0.000439	0.00341	CcSEcCtD
Nadolol—Anorexia—Docetaxel—melanoma	0.000437	0.0034	CcSEcCtD
Nadolol—Rash—Temozolomide—melanoma	0.000435	0.00338	CcSEcCtD
Nadolol—Dermatitis—Temozolomide—melanoma	0.000435	0.00338	CcSEcCtD
Nadolol—Hypotension—Docetaxel—melanoma	0.000429	0.00334	CcSEcCtD
Nadolol—Nausea—Carmustine—melanoma	0.000424	0.0033	CcSEcCtD
Nadolol—Insomnia—Docetaxel—melanoma	0.000415	0.00323	CcSEcCtD
Nadolol—Paraesthesia—Docetaxel—melanoma	0.000412	0.00321	CcSEcCtD
Nadolol—Nausea—Temozolomide—melanoma	0.00041	0.00319	CcSEcCtD
Nadolol—Dyspnoea—Docetaxel—melanoma	0.000409	0.00318	CcSEcCtD
Nadolol—Dyspepsia—Docetaxel—melanoma	0.000404	0.00314	CcSEcCtD
Nadolol—Decreased appetite—Docetaxel—melanoma	0.000399	0.0031	CcSEcCtD
Nadolol—Fatigue—Docetaxel—melanoma	0.000396	0.00308	CcSEcCtD
Nadolol—Pain—Docetaxel—melanoma	0.000392	0.00305	CcSEcCtD
Nadolol—Constipation—Docetaxel—melanoma	0.000392	0.00305	CcSEcCtD
Nadolol—Body temperature increased—Docetaxel—melanoma	0.000363	0.00282	CcSEcCtD
Nadolol—Asthenia—Docetaxel—melanoma	0.000329	0.00256	CcSEcCtD
Nadolol—Pruritus—Docetaxel—melanoma	0.000325	0.00253	CcSEcCtD
Nadolol—Diarrhoea—Docetaxel—melanoma	0.000314	0.00244	CcSEcCtD
Nadolol—Dizziness—Docetaxel—melanoma	0.000303	0.00236	CcSEcCtD
Nadolol—Vomiting—Docetaxel—melanoma	0.000292	0.00227	CcSEcCtD
Nadolol—Rash—Docetaxel—melanoma	0.000289	0.00225	CcSEcCtD
Nadolol—Dermatitis—Docetaxel—melanoma	0.000289	0.00225	CcSEcCtD
Nadolol—Nausea—Docetaxel—melanoma	0.000273	0.00212	CcSEcCtD
Nadolol—ABCB1—Integrated Pancreatic Cancer Pathway—MYC—melanoma	4.36e-05	0.000366	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—KDR—melanoma	4.33e-05	0.000364	CbGpPWpGaD
Nadolol—ADRB2—GPCR downstream signaling—PIK3CG—melanoma	4.32e-05	0.000363	CbGpPWpGaD
Nadolol—ABCB1—Integrated Pancreatic Cancer Pathway—MAPK1—melanoma	4.27e-05	0.000358	CbGpPWpGaD
Nadolol—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—melanoma	4.26e-05	0.000358	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—HDAC2—melanoma	4.21e-05	0.000354	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—FOXO4—melanoma	4.21e-05	0.000354	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—CXCR4—melanoma	4.21e-05	0.000354	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—FN1—melanoma	4.17e-05	0.00035	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—GNAQ—melanoma	4.16e-05	0.00035	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—FOXO4—melanoma	4.12e-05	0.000346	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—HDAC2—melanoma	4.12e-05	0.000346	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—CXCR4—melanoma	4.12e-05	0.000346	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—NOTCH1—melanoma	4.08e-05	0.000343	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—GNAQ—melanoma	4.07e-05	0.000342	CbGpPWpGaD
Nadolol—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—melanoma	4.06e-05	0.000341	CbGpPWpGaD
Nadolol—ABCB1—Integrated Pancreatic Cancer Pathway—KRAS—melanoma	4.03e-05	0.000338	CbGpPWpGaD
Nadolol—ADRB1—Signaling by GPCR—PIK3CG—melanoma	4.01e-05	0.000337	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—CD80—melanoma	4e-05	0.000336	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—APC—melanoma	3.99e-05	0.000335	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—PIK3CG—melanoma	3.99e-05	0.000335	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—KIT—melanoma	3.99e-05	0.000335	CbGpPWpGaD
Nadolol—ADRB3—Signaling by GPCR—NRAS—melanoma	3.99e-05	0.000335	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—EGF—melanoma	3.95e-05	0.000331	CbGpPWpGaD
Nadolol—ADRB2—Signaling by GPCR—PIK3CG—melanoma	3.92e-05	0.00033	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—SYK—melanoma	3.92e-05	0.000329	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—PLA2G6—melanoma	3.89e-05	0.000327	CbGpPWpGaD
Nadolol—ADRB1—GPCR downstream signaling—PIK3CD—melanoma	3.88e-05	0.000326	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—AKT3—melanoma	3.84e-05	0.000323	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—ITGAV—melanoma	3.84e-05	0.000323	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—NGFR—melanoma	3.84e-05	0.000323	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—SYK—melanoma	3.83e-05	0.000322	CbGpPWpGaD
Nadolol—ADRB3—Signaling by GPCR—MAPK3—melanoma	3.82e-05	0.000321	CbGpPWpGaD
Nadolol—ADRB2—GPCR downstream signaling—PIK3CD—melanoma	3.8e-05	0.000319	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—AKT3—melanoma	3.76e-05	0.000316	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—ITGAV—melanoma	3.76e-05	0.000316	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—NGFR—melanoma	3.76e-05	0.000316	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—BRAF—melanoma	3.75e-05	0.000315	CbGpPWpGaD
Nadolol—ABCB1—Integrated Pancreatic Cancer Pathway—PIK3CA—melanoma	3.7e-05	0.000311	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—IGF1—melanoma	3.66e-05	0.000307	CbGpPWpGaD
Nadolol—ADRB3—Signaling by GPCR—MAPK1—melanoma	3.64e-05	0.000306	CbGpPWpGaD
Nadolol—ADRB3—Signaling by GPCR—EGFR—melanoma	3.64e-05	0.000305	CbGpPWpGaD
Nadolol—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—melanoma	3.58e-05	0.000301	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—SOCS1—melanoma	3.56e-05	0.000299	CbGpPWpGaD
Nadolol—ADRB1—Signaling by GPCR—MAP2K1—melanoma	3.55e-05	0.000298	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—S100B—melanoma	3.55e-05	0.000298	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—MAP2K1—melanoma	3.53e-05	0.000297	CbGpPWpGaD
Nadolol—ADRB1—Signaling by GPCR—PIK3CD—melanoma	3.53e-05	0.000296	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—PIK3CD—melanoma	3.51e-05	0.000295	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—VCAN—melanoma	3.5e-05	0.000293	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—SOCS1—melanoma	3.48e-05	0.000292	CbGpPWpGaD
Nadolol—ADRB3—GPCR downstream signaling—PIK3CA—melanoma	3.48e-05	0.000292	CbGpPWpGaD
Nadolol—ADRB2—Signaling by GPCR—MAP2K1—melanoma	3.47e-05	0.000292	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—S100B—melanoma	3.47e-05	0.000292	CbGpPWpGaD
Nadolol—ADRB2—Signaling by GPCR—PIK3CD—melanoma	3.45e-05	0.00029	CbGpPWpGaD
Nadolol—ADRB3—Signaling by GPCR—KRAS—melanoma	3.44e-05	0.000289	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—ERBB4—melanoma	3.39e-05	0.000285	CbGpPWpGaD
Nadolol—ADRB1—GPCR downstream signaling—PIK3CB—melanoma	3.39e-05	0.000284	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—CDKN2B—melanoma	3.37e-05	0.000283	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—FGF2—melanoma	3.36e-05	0.000282	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—ERBB4—melanoma	3.32e-05	0.000279	CbGpPWpGaD
Nadolol—ADRB2—GPCR downstream signaling—PIK3CB—melanoma	3.31e-05	0.000278	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—CDKN2B—melanoma	3.29e-05	0.000276	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—CD86—melanoma	3.25e-05	0.000273	CbGpPWpGaD
Nadolol—ADRB1—GPCR downstream signaling—CXCL8—melanoma	3.25e-05	0.000273	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—EDN1—melanoma	3.23e-05	0.000271	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—CD86—melanoma	3.18e-05	0.000267	CbGpPWpGaD
Nadolol—ADRB2—GPCR downstream signaling—CXCL8—melanoma	3.18e-05	0.000267	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—EDN1—melanoma	3.16e-05	0.000265	CbGpPWpGaD
Nadolol—ADRB3—Signaling by GPCR—PIK3CA—melanoma	3.16e-05	0.000265	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—CSF2—melanoma	3.16e-05	0.000265	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—FGF1—melanoma	3.16e-05	0.000265	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—MDM2—melanoma	3.14e-05	0.000264	CbGpPWpGaD
Nadolol—ADRB1—GPCR downstream signaling—IL2—melanoma	3.11e-05	0.000261	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—ERBB2—melanoma	3.1e-05	0.00026	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—E2F1—melanoma	3.09e-05	0.000259	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—CSF2—melanoma	3.09e-05	0.000259	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—FGF1—melanoma	3.09e-05	0.000259	CbGpPWpGaD
Nadolol—ADRB1—Signaling by GPCR—PIK3CB—melanoma	3.07e-05	0.000258	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—PIK3CB—melanoma	3.06e-05	0.000257	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—PDGFRA—melanoma	3.06e-05	0.000257	CbGpPWpGaD
Nadolol—ADRB2—GPCR downstream signaling—IL2—melanoma	3.04e-05	0.000255	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—ITGB3—melanoma	3.03e-05	0.000254	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—PRKCA—melanoma	3.03e-05	0.000254	CbGpPWpGaD
Nadolol—ABCB1—Integrated Pancreatic Cancer Pathway—AKT1—melanoma	3.02e-05	0.000254	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—E2F1—melanoma	3.02e-05	0.000254	CbGpPWpGaD
Nadolol—ADRB2—Signaling by GPCR—PIK3CB—melanoma	3.01e-05	0.000253	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—PDGFRA—melanoma	2.99e-05	0.000251	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—SPP1—melanoma	2.97e-05	0.000249	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—ITGB3—melanoma	2.96e-05	0.000249	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—PRKCA—melanoma	2.96e-05	0.000249	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—MAP2K2—melanoma	2.96e-05	0.000248	CbGpPWpGaD
Nadolol—ADRB1—Signaling by GPCR—CXCL8—melanoma	2.95e-05	0.000248	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—CYP17A1—melanoma	2.95e-05	0.000248	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—CXCL8—melanoma	2.94e-05	0.000247	CbGpPWpGaD
Nadolol—ADRB3—Signaling by GPCR—HRAS—melanoma	2.92e-05	0.000245	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—SPP1—melanoma	2.9e-05	0.000244	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—MAP2K2—melanoma	2.89e-05	0.000243	CbGpPWpGaD
Nadolol—ADRB2—Signaling by GPCR—CXCL8—melanoma	2.89e-05	0.000243	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—CDKN1B—melanoma	2.87e-05	0.000241	CbGpPWpGaD
Nadolol—ADRB3—GPCR downstream signaling—AKT1—melanoma	2.84e-05	0.000239	CbGpPWpGaD
Nadolol—ADRB1—Signaling by GPCR—IL2—melanoma	2.82e-05	0.000237	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—CASP3—melanoma	2.81e-05	0.000236	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—TERT—melanoma	2.81e-05	0.000236	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—IL2—melanoma	2.81e-05	0.000236	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—RAC1—melanoma	2.81e-05	0.000236	CbGpPWpGaD
Nadolol—ADRB3—Signaling by GPCR—IL6—melanoma	2.8e-05	0.000235	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—GNA11—melanoma	2.79e-05	0.000234	CbGpPWpGaD
Nadolol—ADRB2—Signaling by GPCR—IL2—melanoma	2.76e-05	0.000232	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—TERT—melanoma	2.75e-05	0.000231	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—RAC1—melanoma	2.74e-05	0.00023	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—CCND1—melanoma	2.74e-05	0.00023	CbGpPWpGaD
Nadolol—ABCB1—Transmembrane transport of small molecules—ALB—melanoma	2.73e-05	0.000229	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—FASN—melanoma	2.73e-05	0.000229	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—CTNNB1—melanoma	2.71e-05	0.000228	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—HIF1A—melanoma	2.69e-05	0.000226	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—SLC5A5—melanoma	2.68e-05	0.000225	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—MMP9—melanoma	2.66e-05	0.000223	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—CDKN1A—melanoma	2.65e-05	0.000223	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—PTEN—melanoma	2.64e-05	0.000222	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—HIF1A—melanoma	2.63e-05	0.000221	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—NFKB1—melanoma	2.63e-05	0.000221	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—GNAQ—melanoma	2.59e-05	0.000217	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—CD44—melanoma	2.59e-05	0.000217	CbGpPWpGaD
Nadolol—ADRB3—Signaling by GPCR—AKT1—melanoma	2.58e-05	0.000217	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—KDR—melanoma	2.57e-05	0.000216	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—KDR—melanoma	2.52e-05	0.000211	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—CYP1B1—melanoma	2.48e-05	0.000208	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—FN1—melanoma	2.48e-05	0.000208	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—NOTCH1—melanoma	2.42e-05	0.000204	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—FN1—melanoma	2.42e-05	0.000203	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—VEGFA—melanoma	2.39e-05	0.000201	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—CD80—melanoma	2.37e-05	0.000199	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—NOTCH1—melanoma	2.37e-05	0.000199	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—KIT—melanoma	2.37e-05	0.000199	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—PIK3CG—melanoma	2.37e-05	0.000199	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—APC—melanoma	2.37e-05	0.000199	CbGpPWpGaD
Nadolol—ADRB1—Signaling by GPCR—NRAS—melanoma	2.37e-05	0.000199	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—STAT3—melanoma	2.36e-05	0.000199	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—NRAS—melanoma	2.36e-05	0.000198	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—EGF—melanoma	2.34e-05	0.000197	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—CD80—melanoma	2.32e-05	0.000195	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—APC—melanoma	2.32e-05	0.000195	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—KIT—melanoma	2.32e-05	0.000195	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—PIK3CG—melanoma	2.32e-05	0.000195	CbGpPWpGaD
Nadolol—ADRB2—Signaling by GPCR—NRAS—melanoma	2.32e-05	0.000195	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—EGF—melanoma	2.29e-05	0.000192	CbGpPWpGaD
Nadolol—ADRB1—Signaling by GPCR—MAPK3—melanoma	2.27e-05	0.000191	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—MAPK3—melanoma	2.26e-05	0.00019	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—BRAF—melanoma	2.23e-05	0.000187	CbGpPWpGaD
Nadolol—ADRB2—Signaling by GPCR—MAPK3—melanoma	2.22e-05	0.000186	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—MYC—melanoma	2.2e-05	0.000184	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—BRAF—melanoma	2.18e-05	0.000183	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—IGF1—melanoma	2.17e-05	0.000182	CbGpPWpGaD
Nadolol—ADRB1—Signaling by GPCR—MAPK1—melanoma	2.16e-05	0.000181	CbGpPWpGaD
Nadolol—ADRB1—Signaling by GPCR—EGFR—melanoma	2.16e-05	0.000181	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—MAPK1—melanoma	2.15e-05	0.00018	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—EGFR—melanoma	2.15e-05	0.00018	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—IGF1—melanoma	2.12e-05	0.000178	CbGpPWpGaD
Nadolol—ADRB2—Signaling by GPCR—MAPK1—melanoma	2.11e-05	0.000177	CbGpPWpGaD
Nadolol—ADRB2—Signaling by GPCR—EGFR—melanoma	2.11e-05	0.000177	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—MAP2K1—melanoma	2.1e-05	0.000176	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—PIK3CD—melanoma	2.08e-05	0.000175	CbGpPWpGaD
Nadolol—ADRB1—GPCR downstream signaling—PIK3CA—melanoma	2.06e-05	0.000173	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—MAP2K1—melanoma	2.05e-05	0.000172	CbGpPWpGaD
Nadolol—ADRB1—Signaling by GPCR—KRAS—melanoma	2.04e-05	0.000171	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—PIK3CD—melanoma	2.04e-05	0.000171	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—KRAS—melanoma	2.03e-05	0.00017	CbGpPWpGaD
Nadolol—ADRB2—GPCR downstream signaling—PIK3CA—melanoma	2.02e-05	0.00017	CbGpPWpGaD
Nadolol—ADRB2—Signaling by GPCR—KRAS—melanoma	2e-05	0.000168	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—FGF2—melanoma	1.99e-05	0.000168	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—FGF2—melanoma	1.95e-05	0.000164	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—PRKCA—melanoma	1.88e-05	0.000158	CbGpPWpGaD
Nadolol—ADRB1—Signaling by GPCR—PIK3CA—melanoma	1.87e-05	0.000157	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—MDM2—melanoma	1.87e-05	0.000157	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—ERCC2—melanoma	1.87e-05	0.000157	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—PIK3CA—melanoma	1.87e-05	0.000157	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—ERBB2—melanoma	1.84e-05	0.000155	CbGpPWpGaD
Nadolol—ADRB2—Signaling by GPCR—PIK3CA—melanoma	1.83e-05	0.000154	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—MDM2—melanoma	1.83e-05	0.000153	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—PIK3CB—melanoma	1.82e-05	0.000152	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—TP53—melanoma	1.8e-05	0.000152	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—ERBB2—melanoma	1.8e-05	0.000151	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—PIK3CB—melanoma	1.78e-05	0.000149	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—CXCL8—melanoma	1.75e-05	0.000147	CbGpPWpGaD
Nadolol—ADRB1—Signaling by GPCR—HRAS—melanoma	1.73e-05	0.000146	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—HRAS—melanoma	1.73e-05	0.000145	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—CXCL8—melanoma	1.71e-05	0.000143	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—CDKN1B—melanoma	1.7e-05	0.000143	CbGpPWpGaD
Nadolol—ADRB2—Signaling by GPCR—HRAS—melanoma	1.7e-05	0.000142	CbGpPWpGaD
Nadolol—ADRB1—GPCR downstream signaling—AKT1—melanoma	1.69e-05	0.000142	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—CASP3—melanoma	1.67e-05	0.00014	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—IL2—melanoma	1.67e-05	0.00014	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—CDKN1B—melanoma	1.67e-05	0.00014	CbGpPWpGaD
Nadolol—ADRB1—Signaling by GPCR—IL6—melanoma	1.66e-05	0.000139	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—IL6—melanoma	1.65e-05	0.000139	CbGpPWpGaD
Nadolol—ADRB2—GPCR downstream signaling—AKT1—melanoma	1.65e-05	0.000138	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—CASP3—melanoma	1.63e-05	0.000137	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—IL2—melanoma	1.63e-05	0.000137	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—CCND1—melanoma	1.63e-05	0.000137	CbGpPWpGaD
Nadolol—ADRB2—Signaling by GPCR—IL6—melanoma	1.62e-05	0.000136	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—CTNNB1—melanoma	1.61e-05	0.000135	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—CCND1—melanoma	1.59e-05	0.000134	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—MMP9—melanoma	1.58e-05	0.000133	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—CTNNB1—melanoma	1.58e-05	0.000132	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—CDKN1A—melanoma	1.57e-05	0.000132	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—PTEN—melanoma	1.57e-05	0.000132	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—NFKB1—melanoma	1.56e-05	0.000131	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—MMP9—melanoma	1.54e-05	0.00013	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—CDKN1A—melanoma	1.54e-05	0.000129	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—PTEN—melanoma	1.54e-05	0.000129	CbGpPWpGaD
Nadolol—ADRB1—Signaling by GPCR—AKT1—melanoma	1.53e-05	0.000129	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—NFKB1—melanoma	1.53e-05	0.000128	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—AKT1—melanoma	1.52e-05	0.000128	CbGpPWpGaD
Nadolol—ADRB2—Signaling by GPCR—AKT1—melanoma	1.5e-05	0.000126	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—PIK3CG—melanoma	1.47e-05	0.000124	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—PPARG—melanoma	1.42e-05	0.000119	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—VEGFA—melanoma	1.42e-05	0.000119	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—STAT3—melanoma	1.4e-05	0.000118	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—NRAS—melanoma	1.4e-05	0.000118	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—VEGFA—melanoma	1.39e-05	0.000116	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—STAT3—melanoma	1.37e-05	0.000115	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—NRAS—melanoma	1.37e-05	0.000115	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—MAPK3—melanoma	1.34e-05	0.000113	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—MAPK3—melanoma	1.31e-05	0.00011	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—MYC—melanoma	1.3e-05	0.00011	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—PIK3CD—melanoma	1.3e-05	0.000109	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—ALB—melanoma	1.28e-05	0.000107	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—MAPK1—melanoma	1.28e-05	0.000107	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—MYC—melanoma	1.28e-05	0.000107	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—EGFR—melanoma	1.28e-05	0.000107	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—MAPK1—melanoma	1.25e-05	0.000105	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—EGFR—melanoma	1.25e-05	0.000105	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—KRAS—melanoma	1.21e-05	0.000101	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—KRAS—melanoma	1.18e-05	9.9e-05	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—PIK3CB—melanoma	1.13e-05	9.48e-05	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—PTGS2—melanoma	1.12e-05	9.39e-05	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—PIK3CA—melanoma	1.11e-05	9.3e-05	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—PIK3CA—melanoma	1.08e-05	9.09e-05	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—TP53—melanoma	1.07e-05	8.99e-05	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—TP53—melanoma	1.05e-05	8.8e-05	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—HRAS—melanoma	1.02e-05	8.6e-05	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—HRAS—melanoma	1e-05	8.41e-05	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—IL6—melanoma	9.8e-06	8.23e-05	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—PTEN—melanoma	9.76e-06	8.19e-05	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—IL6—melanoma	9.59e-06	8.05e-05	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—AKT1—melanoma	9.04e-06	7.59e-05	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—AKT1—melanoma	8.85e-06	7.43e-05	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—PIK3CA—melanoma	6.88e-06	5.78e-05	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—AKT1—melanoma	5.62e-06	4.72e-05	CbGpPWpGaD
